G9pharma co., LTD reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was KRW 15,562.56 million compared to KRW 7,024.19 million a year ago. Basic loss per share from continuing operations was KRW 3,815 compared to KRW 1,878 a year ago. Diluted loss per share from continuing operations was KRW 3,815 compared to KRW 1,878 a year ago. Basic loss per share was KRW 3,815 compared to KRW 1,878 a year ago.
For the nine months, net loss was KRW 28,884.83 million compared to KRW 31,929.06 million a year ago. Basic loss per share from continuing operations was KRW 7,082 compared to KRW 8,980 a year ago. Diluted loss per share from continuing operations was KRW 7,082 compared to KRW 8,980 a year ago. Basic loss per share was KRW 7,082 compared to KRW 8,980 a year ago.